PDGFRA and neoplasm: When considering only patients with localised disease for whom molecular data were available (n=94), KIT exon 9, 11, 13 and 17 mutations were found in 9 (10%), 49 (52%), 3 (3%) and 1 (1%) patient, respectively, whereas PDGFRA mutations were found in 14 (15%) patients (exon 18, n=12 and exon 12, n=2), and 18 (19%) patients had KIT and PDGFRA wild-type tumours.